New research reveals that people who discontinue blockbuster GLP-1 drugs like Wegovy and Mounjaro tend to recover reduced body mass at a significantly accelerated pace than those who stop conventional diet and exercise plans.
Published data in a prominent medical journal shows that while obese people can lose a large proportion of their body weight while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"Users buying such drugs must be aware of the risk of rapid weight regain when the medication ends," stated researcher Dr. Susan Jebb.
This pace of regain implies a return to pre-treatment mass in about one and a half years.
Weighing Treatments
The study, which looked at 37 of studies involving over 9,000 of patients, contrasted the outcomes of GLP-1 agonists with other pills.
Scientists note that individuals who lose weight through dieting typically see a slower creep back—perhaps 100 grams monthly—post-intervention.
Understanding the Fast Rebound
Experts believe the way of the drugs is key to understanding the accelerated rebound.
The injections copy a body's own chemical called GLP-1, which moderates hunger.
"Artificially providing GLP-1 concentrations several times higher than normal may cause the body to produce less of its own natural hormone, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Stopping of this medication results in hunger is uncontrolled, making overeating a significant risk."
A Lifelong Condition?
Health authorities recommend the injections for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
A number of clinicians contend that, given the high risk of relapse, the treatment should be considered long-term.
This view is echoed by pharmaceutical companies, who note that the findings "emphasize the chronic character of obesity," comparing it to managing conditions like diabetes.
Patient Accounts
Individuals who have come off the medication explain a intense return of cravings.
"I experienced a switch flipping and I was suddenly extremely hungry," said one woman.
This challenge is compounded if individuals have not developed permanent dietary or behavioural modifications during treatment.
Widespread Interest
Survey data show that millions of people in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.
- Use is more common among females than men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
In conclusion, researchers emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone cure and lasting health benefits hinges on combined behavioural management.
